Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Acknowledgement is hereby made of receipt and entry of the communication filed on Dec. 19, 2024. Claims 24-41 are pending and currently examined.
Information Disclosure Statement
The information disclosure statement submitted on Dec. 19, 2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. The IDS contains Foreign Patent Documents and Non-Patent Literature Documents that are not in English language. The documents not provided in English language are considered only to the extent of the Examiner’s capacity of the related for foreign language and the English language submission. An initialed and dated copy of Applicant’s IDS form is attached to the instant Office action.
Double Patenting Rejection
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
Claims 24-41 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-23 of US Patent 11,203,629.
Although the conflicting claims are not identical, they are not patentably distinct from each other. Both sets of claims encompass a LAMP construct comprising a heterologous antigenic domain placed between two homology domains in the luminal region of the LAMP protein. The differences/correlations between the two sets of claims include: (1) the instant claims require that the LAMP construct comprises the two homology domains of a LAMP-1 protein, while only the reference claims 5-8 specify LAMP-1 and other reference claims are generic in the LAMP protein types; (2) instant claims specify a polynucleotide encoding the LAMP construct, while reference claims 1-10 and 18-23 specify polypeptide of the LAMP construct and only claims 11-14 specify an encoding polynucleotide; (3) instant claims 28-29 and 31-35 specify SEQ ID NO: 1 for the LAMP-1 protein, while reference claims 6-7 specify SEQ ID NO: 1 for LAMP-1; (4) instant claims 31-35 specify amino acid positions in SEQ ID NO: 1 flanking structural regions of the LAMP-1 protein, while reference claims are silent on such positions; (5) instant claims 37, 39 and 40 respectively specify a self-replicating RNA viral vector, an isolated antigen-presenting cell, and more specifically dendritic cell, comprising the polynucleotide encoding the LAMP construct, while references claims are silent on these limitations; and (6) the instant claims require that the LAMP construct further comprises a transmembrane domain of a LAMP protein, a cytoplasmic tail of a LAMP protein, and a signal sequence and the relative position of the transmembrane and cytoplasmic domain, while this limitation is only partially specified by some reference claims.
Among the above 6 differences/correlation between the two sets of claims, only points (4) and (5) are absent or partially absent in reference claims. Regarding (4), since the amino acid positions separating the recited structural features of the LAMP-1 protein with SEQ ID NO: 1, one of skill in the art would have envisaged that the LAMP-1 protein with SEQ ID NO: 1 recited in reference claims 6-7 would inherently have the same structural features with the same amino acid boundaries.
Regarding (5), McCullough et al. (Vaccines 2014, 2, 735-754) reviews studies on self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. The review presents how such advances are being applied to the delivery of a new form of RNA vaccine, replicons (RepRNA) carrying inserted foreign genes of interest encoding vaccine antigens. Approaches have been developed for delivery to DCs, leading to the translation of the RepRNA and encoded vaccine antigens both in vitro and in vivo. The review relates the DC endocytic pathways to immune response induction, and the potential advantages for these self-replicating RNA vaccines in the near future. See Abstract.
Based on teachings of McCullough, it is known practice to include polynucleotide encoding antigen genes in viral RNA replicons and to introduce such expression constructs into dendritic cells. Therefore, one of skill in the art would have found it obvious to include the polynucleotide encoding the LAMP construct of the reference claims in a viral RNA replicon vector and introduce the vector into dendritic cells for further applications, arriving at the instant claims 37, 39 and 40.
Accordingly, claims 24-41 are unpatentable over claims 1-23 of US Patent 11,203,629.
Claims 24-41 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-31 of US Patent 11,773,153.
Although the conflicting claims are not identical, they are not patentably distinct from each other. Both sets of claims encompass a LAMP construct comprising a heterologous antigenic domain placed between the two homology domains in the LAMP-1 protein. The differences/correlations between the two sets of claims include: (1) reference claims 2-5, 8-13 and 28-31 specify structural feature of the LAMP-1 protein, specifically the LAPM-1 with SEQ ID NO: 1, correlating to instant claims 25-35; (2) reference claims 6-7 specify a linker between the two homology domains and the antigenic domain, correlating to instant claims 26-27; (3) reference claims 14-17, 19-20 specify a polynucleotide encoding the claimed LAMP-1 construct, correlating to instant claims 24-41; (4) reference claim 21-27 specify a method of administering the LAMP-1 construct, correlating to instant claim 41; (5) instant claims 37, 39 and 40 respectively specify a self-replicating RNA viral vector, an isolated antigen-presenting cell, and more specifically dendritic cell, comprising the polynucleotide encoding the LAMP construct, while references claims are silent on these limitations; and (6) the instant claims require that the LAMP construct further comprises a transmembrane domain of a LAMP protein, a cytoplasmic tail of a LAMP protein, and a signal sequence and the relative position of the transmembrane and cytoplasmic domain, while this limitation is only partially specified by some reference claims.
Among the above 6 differences/correlation between the two sets of claims, only point (5) is absent or partially absent in reference claims. McCullough et al. (Vaccines 2014, 2, 735-754) reviews studies on self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. The review presents how such advances are being applied to the delivery of a new form of RNA vaccine, replicons (RepRNA) carrying inserted foreign genes of interest encoding vaccine antigens. Approaches have been developed for delivery to DCs, leading to the translation of the RepRNA and encoded vaccine antigens both in vitro and in vivo. The review relates the DC endocytic pathways to immune response induction, and the potential advantages for these self-replicating RNA vaccines in the near future. See Abstract.
Based on teachings of McCullough, it is known practice to include polynucleotide encoding antigen genes in viral RNA replicons and to introduce such expression constructs into dendritic cells. Therefore, one of skill in the art would have found it obvious to include the polynucleotide encoding the LAMP construct of the reference claims in a viral RNA replicon vector and introduce the vector into dendritic cells for further applications, arriving at the instant claims 37, 39 and 40.
Accordingly, claims 24-41 are unpatentable over claims 1-31 of US Patent 11,773,153.
Claims 24-41 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-28 of US Patent 12,116,396.
Although the conflicting claims are not identical, they are not patentably distinct from each other. Both sets of claims encompass a polynucleotide encoding a LAMP construct comprising a heterologous antigenic domain placed between two homology domains in the LAMP protein. The differences/correlations between the two sets of claims include: (1) reference claims 1-6, 18-22 and 28 are generic in the LAMP protein, references claims 7-17 and 23-27 specify LAMP-1, while all instant claims specify LAMP-1; (2) reference claims 4-5 specify a linker, correlating to instant claims 26-27; (3) references claims 8-9 and 11-17 specify structural features of LAMP-1 protein, specifically the LAPM-1 with SEQ ID NO: 1, correlating to instant claims 25-35; (4) reference claim 28 specifies a method of administering the LAMP-1 construct, correlating to instant claim 41; (5) reference claims 18-27 specify a self-replicating RNA viral vector, and/or an isolated antigen-presenting cell, and more specifically dendritic cell, comprising the polynucleotide encoding the LAMP construct, correlating to instant claims 37, 39 and 40; and (6) the instant claims require that the LAMP construct further comprises a transmembrane domain of a LAMP protein, a cytoplasmic tail of a LAMP protein, and a signal sequence and the relative position of the transmembrane and cytoplasmic domain, while this limitation is only partially specified by some reference claims. Since the two sets of claims encompass each other in scopes, the instant claims are obvious over the reference claims.
Accordingly, claims 24-41 are unpatentable over claims 1-28 of US Patent 12,116,396.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIANXIANG (NICK) ZOU whose telephone number is (571)272-2850. The examiner can normally be reached on Monday - Friday, 8:30 am - 5:00 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MICHAEL ALLEN, on (571) 270-3497, can be reached. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/NIANXIANG ZOU/Primary Examiner, Art Unit 1648